Background: We conducted co-clinical trials in patient-derived xenograft (PDX) models to identify predictive biomarkers for the multikinase inhibitor dovitinib in lung squamous cell carcinoma (LSCC).
Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide [1, 2] . Contrast to lung adenocarcinoma [1] [2] [3] , effective targeted therapy for lung squamous cell carcinoma (LSCC) has remained elusive. Recently, The Cancer Genome Atlas (TCGA) identified numerous exonic mutations, genetic rearrangements and copy number alterations in LSCC. One of the newly recognized molecular targets in LSCC is fibroblast growth factor receptor (FGFR) gene. Our group and others have reported that FGFR1 amplification was found in LSCC patients at a frequency of 13-22% and was associated with poor prognosis [3] [4] [5] . A number of FGFR-targeted agents are currently being developed in LSCC patients with FGFR alterations [6] .
Dovitinib is an oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFRs) 1 to 3, FGFRs 1 to 3, and KIT. On the basis of FGFR1 amplification as a druggable target in LSCC [3] , we embarked on a phase II study (NCT01861197) of dovitinib in LSCC patients with FGFR1 amplification, resulting in only a limited clinical activity [6] . Other FGFR-targeted agents, such as AZD4547 and BGJ398, in FGFR-amplified malignancies has produced disappointing clinical outcomes, raising a question whether the FGFR amplification is a predictive biomarker to FGFRtargeted agents [7, 8] . Therefore, the identification of predictive biomarkers for FGFR-targeted agents has remained a crucial issue.
To circumvent the limited predictive values of conventional preclinical models [9, 10] , there has been increasing attention in the development of patient-derived tumor xenograft (PDX) models [11] . The PDX models, which were created by direct implantation of patient's tumor in immunodeficient mice, have shown to reflect principal histologic and genetic characteristics of original patient tumors and retain tumor heterogeneity better than any other models [4, 12] . The PDX model may be used in the application of 'co-clinical trial' approach, in which it is developed from a patient enrolled in a clinical trial and treated with the same experimental agents to emulate clinical response. This strategy permits the assessment of drug response simultaneously in the patient and mouse model, providing an interesting platform to investigate resistance mechanism, predictive biomarkers and novel combination strategies in a real-time manner.
The aim of the study was to investigate predictive biomarkers of dovitinib in LSCC. Here we used PDX models, which faithfully replicated the histologic, genomic and pharmacologic features observed in the original patients, to conduct 'co-clinical trial' that mirror a phase II trial of dovitinib in FGFR1-amplified LSCC.
Methods Patients
To establish LSCC PDX models, a total of five tumor samples were obtained directly from two patients with advanced LSCC treated with dovitinib in a prospective phase II trial (NCT01861197) and three patients with early-stage LSCC receiving surgery. Tumors and paired peripheral blood samples were collected prior to dovitinib treatment. The tumor characteristics and the response to dovitinib were described (supplementary Table  S5 , available at Annals of Oncology online). This study was conducted under approval by institutional review boards of Severance Hospital.
Establishment of PDX models
To establish PDX models, 6-8-week-old female severe combined immunodeficient (NOG) and nude (nu/nu) mice (OrientBio, Seoul, Korea) were used. Tumor tissue obtained from F1 mice were excised and cut into small (3Â3Â3 mm 3 ) fragments and then implanted s.c. in a group of six to seven mice for each patient. When the tumors size reached $1.5 cm in diameter, they were excised and dissected into 3Â3Â3 mm 3 fragments and implanted into another set of mice according to the same procedure. The passage harboring the patient-derived material was termed F0, with subsequent generations numbered consecutively (F1, F2, F3, and so on) [13] . The F3 was expanded for in vivo drug efficacy test. 
In vivo drug treatment

Histology
Tissues from all PDX models were harvested and fixed in 10% buffered formalin within 30 min after resection. Tissues were processed following the routine H&E staining procedure and reviewed by a pathologist to confirm the LSCC diagnosis.
Gene copy number
FISH to detect FGFR1 amplification was performed following routine method depicted in Online method.
Whole exome sequencing and somatic variants
We performed DNA sequencing of original tumors, PDX, and matched peripheral blood by Illumina HiSeq2500 platform. Details were depicted in Online method.
Inference of copy number alterations from exome sequencing data
We used read-depth based copy number inference algorithm of VarScan2 [15] . Details were depicted in Online method.
Microarray-based gene expression profiling
Gene expression profiling was conducted using Human HT-12v4.0 Expression Beadchip arrays. Detailed method was depicted in Online method.
Statistical analysis
Results are presented as the mean standard deviation for at least three experiments for each group. Statistical differences were determined using ANOVA and the Wilcoxon rank sum test for independent samples. Treatment differences with respect to survival were assessed via the logrank test. A P value of <0.05 was considered statistically significant.
Results
Morphologic and pathologic similarity in PDX models
We established PDX-01 and -02 directly from advanced, previously treated LSCC patients to conduct a mouse-human co-clinical trial ( Figure 1A ). Additionally, PDX-03 -04 and -05 were established from surgically resected LSCC. Histology and FGFR1 gene signal of PDX tumors (F2) were well-matched with those of primary tumors (F0) ( Figure 1B ). PDX-01 and -02 were identified as low-level FGFR1-amplified tumors. 
Faithful replication of clinical response to dovitinib in PDX models
To evaluate whether preclinical responses in PDX models were predictive of clinical response in patients, we treated PDX-01 and -02 with dovitinib in parallel with treating LSCC patients with the same drug in a prospective trial. The PDX-01 displayed rapid tumor regression sustained for >30 days (Tumor growth inhibition (TGI) ¼ 116.3%; P < 0.001) ( Figure 2 ). In contrast, PDX- 02 displayed rapid tumor growth for a period of 15 days followed by modest tumor growth inhibition in response to dovitinib compared to control (TGI¼ 63.6%; P ¼ 0.04) (Figure 2 ). Importantly, preclinical responses to dovitinib in PDX-01 and -02 were precisely replicated in clinical responses of the corresponding patients enrolled in the clinical trial. The patient, from whom PDX-01 was derived, showed a partial response to dovitinib with progressionfree survival of 6 months, whereas the patient, from whom PDX-02 was derived, showed rapid disease progression within 2 months ( Figure 2 Original article Annals of Oncology these F2 tumors (Figure 2) . PDX-03 and -04 displayed relatively poor antitumor efficacy in response to dovitinib. PDX-05 demonstrated significant tumor growth inhibition in response to dovitinib compared to control (TGI ¼ 109.6%, P < 0.0001). Dovitinib induced a significant increase in apoptosis and decrease of proliferation in PDX-01 and -05 compared to PDX-02, -03, and -04 (P < 0.001) (Figure 2 and supplementary Figure S1 , available at Annals of Oncology online).
Analysis of genome-wide copy number profiles in PDX tumors
To compare genomic characteristics of xenograft tumors (F2) with those of case-matched original tumors (F0), we first investigated copy number alterations. The genome-wide copy number profiles inferred from the sequencing read-depth (tumor-versusnormal ratio) from whole exome sequencing (WES) are shown in supplementary Figure S2 , available at Annals of Oncology online.
The genome-wide copy number profiles of PDX-01 F0 and F2 are largely concordant with each other. Importantly, amplification of FGFR1 was consistently observed across the cases. However, the FGFR1 amplifications in these cases are largely due to the arm-level 8p gains, not due to focal amplifications as previously reported (supplementary Figure S2 , available at Annals of Oncology online) [5] . When we investigate 497 LSCC copy number profiles from TCGA, all the high-level FGFR1 amplifications (log2 ratio > 1.0) occurred in 52 focal segments as large as 90.3 kb to 9.02 Mb (median of 1.4 Mb), while moderate-level FGFR1 amplifications were observed in 121 segments as large as 252.1 kb to 144.6 Mb (median of 9.4 Mb) (supplementary Figure  S2 , available at Annals of Oncology online) [16] . This supports that high-level amplifications of FGFR1 are likely to be focal events instead of chromosomal arm-level 8q gains while the moderate-level, large 8q gains as observed across all the PDX tumors in this study, are unlikely to be a predictor for dovitinib sensitivity.
Genomic fidelity of PDX tumors in terms of somatic mutations
To examine genomic fidelity of PDX tumors, we compared WES from two originating tumors [PDX-(01-02)-F0] and counterpart PDX tumors [PDX-(01-02)-F2]. Two types of somatic mutations were identified by comparing the tumor with matched normal sequencing data, i.e. single nucleotide variants (SNV) and small insertions/deletions (indels). We observed a substantial overlap between the F0 and F2 mutations in that 80.1% and 86.7% of F0 somatic mutations can be identified in F2 of PDX-01 and -02, respectively (supplementary Figure S3 , available at Annals of Oncology online). Additionally, we observed that the F0-or F2-specific mutations are largely subclonal with lower mutant allele frequencies (MAF) compared to F0-or F2-common mutations. This suggests that the somatic mutations of the originating tumors (F0) were largely preserved upon transplantation, but some of F0 mutations, especially subclonal ones, may be lost during passages. We also observed that the MAF of F0-and F2-common mutations showed an overall concordance (r 2 ¼ 0.86 and 0.27 for PDX-01 and -02, respectively) suggesting that the subclonal architecture of somatic mutations in parental tumors is largely maintained in PDX tumor (supplementary Figure S3 , available at Annals of Oncology online).
Analysis of somatic mutation profiles in PDX tumors
In an attempt to identify potential somatic mutations conferring the sensitivity to dovitinib, we focused on known cancer-relevant genes based on TARGET database [17] . Non-silent mutations including the missense mutations on TARGET genes are listed in supplementary Table S1 , available at Annals of Oncology online. The majority of missense mutations on known cancer genes were located outside of the known hotspots, i.e. FGFR2 (PDX-02, p.T73N), KIT (p.F110I in PDX-02 and p.L426I in PDX-03), and PDGFRB (PDX-01, p.E198Q) [18, 19] . No somatic mutations were observed for the other targets of dovitinib (VEGFR1, 2, 3 and FLT3), suggesting that no confirmative prediction markers for dovitinib in terms of the mutational landscape of the LSCC.
FGFR gene expression signatures are predictors for response to dovitinib
To elucidate predictive determinants for the sensitivity of dovitinib, we performed microarray-based gene expression profiling of five PDX cases. We first examined differentially expressed genes between the responders (PDX-01 and -05) and non-responders (PDX-02-04). Among the top 50 up-regulated genes in PDX-01 and PDX-05 ( Figure 3A and B), we note FGF3 and FGF19 are commonly up-regulated in these two responders compared to non-responders. Supplementary Figure S4 , available at Annals of Oncology online, shows the detailed list of up-and downregulated genes in the two responders with the corresponding heatmaps. We further performed gene set enrichment analysis (GSEA) to identify which molecular functions. Of note, the comparison of top enriched 20 molecular categories in the KEGG/ REACTOME database revealed that four FGFR-related pathways are commonly up-regulated both in PDX-01 and PDX-05 compared to non-responders (supplementary Table S2 , available at Annals of Oncology online). The representative function of 'FGFR ligand binding and activation' is illustrated for the enrichment plot and their belonging genes in the expression heatmap ( Figure  3C and D for PDX-01 and PDX-05, respectively). Our result highlights FGFR pathway activation as a potential molecular determinant for sensitivity to dovitinib whose activity can be evaluated with gene expression profiling.
FGFR signaling module performed well in the prediction of dovitinib sensitivity
To identify predictive gene expression signatures from independent datasets, we collected 91 lung cancer celllines that are available both for the gene expression profiles and in vitro sensitivity to dovitinib (IC50) in the Cancer Cell Line Encyclopedia (CCLE) database. According to the level of IC50 to dovitinib, we classified 91 lung cancer cell lines into sensitive, intermediate and resistant lines by k-means clustering (12) (n ¼ 9, 18 and 64, respectively; Figure 4A and supplementary Table S3 , available at Annals of Oncology online). We next performed GSEA and identified 15 and 5 molecular terms that are significantly activated or repressed in dovitinib-sensitive lung cancer cell lines compared to resistant lines (adjusted P < 0.05; supplementary Table S4 , available at Annals of Oncology online). Of note, the comparison of dovitinibsensitive with -resistant cell lines rediscovered two gene sets (FGFR ligand binding/activation and SHC-mediated cascade pathway) differentially expressed between dovitinib-responders (PDX-01 and PDX-05) and non-responders (PDX-02-04). To summarize the redundant molecular terms, we collected leading edge gene subsets for 15 gene sets and generated module maps ( Figure 4B ). Five modules were identified including those representing "FGFR pathway" (module 1) along with those of "Degradation", "Myogenesis", "Immune", and "Mitosis, RNA metabolism". To test the performance of modules identified for the prediction of sensitivity to dovitinib, we merged the expression of 91 CCLE lung cancer celllines and those of five PDX patients after batch effect adjustment ( Figure 4C) . Notably, we observed that module 1 can segregate the responders (PDX-01 and -05) from non-responders (PDX-02-04) in a concordant manner with cell lines. This segregation of PDX tumors was not observed for other modules (supplementary Figure S5 , available at Annals of Oncology online).
Discussion
In this study, we successfully established PDX models from advanced-stage LSCC patients in a human-mouse co-clinical trial. Importantly, the current study is the first reported coclinical trial conducted in conjunction with a phase II clinical trial. We demonstrated that histologic and genetic profiles were highly preserved between originating tumors and corresponding PDX tumors. Notably, the responses to dovitinib in LSCC patients enrolled in the clinical trial were replicated in PDX models. FGF19  FGF3  FGFR3  FGF18  FGF17  FGFR2  FGF20  FGF23  FGF8  KL  FGF22  FGF6  FGF4  FGFR4  FGF9  FGF10  FGF7  FGF1  FGFR1  KLB  FGF5  FGF2   FGF3  FGF19  FGFR3  FGF17  FGFR2  FGF5  FGF20  FGFR1  FGF9  FGF18  KL  FGF23  FGF22  FGF8  FGF10  FGF6  FGF7  FGF4  KLB  FGFR4  FGF1  FGF2 PDX-01
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PDX-03 PDX-04 The gene expression analysis revealed that gene sets associated with FGFR pathway activation is a key molecular determinant for the sensitivity to dovitinib, which can significantly contribute to clinical development of dovitinib and other FGFR inhibitors in LSCC.
Preclinical studies clearly showed that FGFR1 amplification confers dependence on FGFR signaling [5, 14] . Based on these results, FGFR1 amplification has been considered as a key molecular characteristic to select patients most likely to benefit from FGFR-targeted therapy [5, 20] . However, the clinical results of selective FGFR inhibitors or multikinase inhibitors including dovitinib were somewhat disappointing with overall responses of $10-20% in biomarker-selected population [21] . Consistent with little predictive value of FGFR1 amplification in previous studies, genome-wide copy number analysis revealed that FGFR1 amplification was largely due to arm-level 8p gain, but not focal amplification, highlighting that FGFR1 amplification may not be a predictor for dovitinib. Additional biomarkers have been proposed to predict sensitivity to FGFR inhibitors, including FGFR1 mRNA expression, elevated FGF ligands or activation of downstream signals, but which one to use in a clinical setting remains controversial. The potential role of these biomarkers in selecting patients most likely to benefit to FGFR inhibitors is being evaluated in ongoing clinical trials [6, 22] .
In our study, comparison of gene expression profiles between the responder and non-responders revealed a number of differentially expressed genes including FGF3 and FGF19. GSEA further showed that four FGFR signaling pathway-related gene sets were commonly up-regulated in two responders (PDX-01 and -05), compared to non-responders (PDX-02-04). Notably, using independent dataset, we confirmed that these two gene sets were significantly enriched in dovitinib-sensitive cell, compared to resistant cell lines. Our findings suggest that FGFR pathway activation may represent a key molecular determinant for sensitivity to dovitinib.
There is urgent need for preclinical models with strong translational potential to test the efficacy of targeted therapies in advanced LSCC patients [23] . We have difficulties in acquisition of sufficient tumor tissue by needle biopsy in advanced LSSC patients. PDX platform can overcome aforementioned limitation of developing biomarker by sufficient PDX tumor tissue originated from specific patients. The patient-specific PDX platform can be potentially used to screen not only for the most effective "molecularly guided targeted therapy", but also for the identification of predictive biomarkers to guide further personalized therapy and drug development [24] .
It usually takes several months to establish the first PDX (F0), even though only 2-5 weeks is needed for subsequent passaging of PDXs [25] . This long time lapse makes the PDX platform more of a research tool, especially in cancers with rapid disease progression and short patient survival [11] . It is necessary to improve engraftment rates, decrease delay between engraftment time and patient treatment initiation.
In conclusion, we showed that co-clinical trial approach provides an interesting platform to investigate predictive biomarkers to targeted therapy in a real-time manner. Our data showed that overexpression of gene sets associated with FGFR pathway activation could be a potential biomarker for FGFR inhibitor in LSCC patients.
